ALMS
Alumis Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2024-06-28
$10.74
+0.39 (+3.80%)
last quote
Want the full multi-source brief on ALMS?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$10.74
High
$10.80
Low
$10.31
Previous close
$10.35
Fundamentals
Market cap
$3.11B
P/E (TTM)
—
P/S (TTM)
129.40x
P/B
3.38x
Gross margin
—
Operating margin
-1109.09%
Net margin
-1013.23%
Rev growth (YoY)
—
EPS growth (YoY)
—
ROE
-54.71%
52W high
$31.35
52W low
$3.76
Beta
0.68x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-11in 68 days
Q3 2026EPS est $-0.77Rev est $1.7M
Recent SEC filings
CIK 1847367filing-language history →
Recent news
2026-08-27 → 2026-09-03
Benzinga · 1d
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $55 to $37.
Benzinga · 1d
Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25
Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $51 to $25.
Benzinga · 1d
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
Benzinga · 1d
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.
Benzinga · 1d
Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29
Morgan Stanley analyst Terence Flynn maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $39 to $29.
Benzinga · 1d
HC Wainwright & Co. Upgrades Alumis to Buy, Lowers Price Target to $15
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Alumis (NASDAQ:ALMS) from Neutral to Buy and lowers the price target from $25 to $15.
ChartMill · 1d
Here are the top movers in Tuesday's session.
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
SeekingAlpha · 1d
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ALMS stock.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial